Genetic microarrays applied to hematologic malignancies identified a number of subgroups with a defined gene expression pattern, which were not identified by morphology, cytogenetics or molecular genetics. In many cases, these expression patterns links tumor cells to the normal developmental counterpart, and represent distinct disease subgroups with different clinical presentations and outcomes. Furthermore, genetic microarrays will be useful in predicting prognosis and identifying novel target of therapy.